Shares of Eli Lilly & Co. LLY slid 3.00% to $844.27 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.01% to 6,114.63 and Dow ...
Investors in Eli Lilly (Symbol: LLY) saw new options begin trading today, for the March 2026 expiration. One of the key data points that goes into the price an option buyer is willing to pay ...
Eli Lilly (NYSE:LLY) is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are expected ...
View Eli Lilly and Company (LLY) current and estimated P/E ratio data provided by Seeking Alpha.
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.
Hosted on MSN1mon
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 ProjectionsShares of Eli Lilly & Co. dropped over 7% on Tuesday morning ... bullish,’ with the ticker climbing to the top five trending symbols list amid a spike in message volume. Many retail investors ...
At Holdings Channel, we have reviewed the latest batch of the 31 most recent 13F filings for the 12/31/2024 reporting period, and noticed that Eli Lilly (Symbol: LLY) was held by 22 of these funds.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...
Eli Lilly LLY-N on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback